CA3019146C - Oxysterols and methods of use thereof - Google Patents

Oxysterols and methods of use thereof Download PDF

Info

Publication number
CA3019146C
CA3019146C CA3019146A CA3019146A CA3019146C CA 3019146 C CA3019146 C CA 3019146C CA 3019146 A CA3019146 A CA 3019146A CA 3019146 A CA3019146 A CA 3019146A CA 3019146 C CA3019146 C CA 3019146C
Authority
CA
Canada
Prior art keywords
compound
disorder
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3019146A
Other languages
English (en)
French (fr)
Other versions
CA3019146A1 (en
Inventor
Albert Jean Robichaud
Francesco G. Salituro
Gabriel MARTINEZBOTELLA
Boyd L. Harrison
John Gregory Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CA3019146A1 publication Critical patent/CA3019146A1/en
Application granted granted Critical
Publication of CA3019146C publication Critical patent/CA3019146C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3019146A 2016-04-01 2017-03-31 Oxysterols and methods of use thereof Active CA3019146C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317002P 2016-04-01 2016-04-01
US62/317,002 2016-04-01
PCT/US2017/025535 WO2017173358A1 (en) 2016-04-01 2017-03-31 Oxysterols and methods of use thereof

Publications (2)

Publication Number Publication Date
CA3019146A1 CA3019146A1 (en) 2017-10-05
CA3019146C true CA3019146C (en) 2024-03-26

Family

ID=59965335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019146A Active CA3019146C (en) 2016-04-01 2017-03-31 Oxysterols and methods of use thereof

Country Status (20)

Country Link
US (3) US20190330259A1 (OSRAM)
EP (1) EP3436022B1 (OSRAM)
JP (4) JP7112331B2 (OSRAM)
CN (2) CN109195604B (OSRAM)
AU (3) AU2017240157B2 (OSRAM)
CA (1) CA3019146C (OSRAM)
CY (1) CY1125230T1 (OSRAM)
DK (1) DK3436022T3 (OSRAM)
ES (1) ES2921010T3 (OSRAM)
HR (1) HRP20220716T1 (OSRAM)
HU (1) HUE059491T2 (OSRAM)
LT (1) LT3436022T (OSRAM)
MA (1) MA44526A (OSRAM)
PL (1) PL3436022T3 (OSRAM)
PT (1) PT3436022T (OSRAM)
RS (1) RS63280B1 (OSRAM)
RU (1) RU2754130C2 (OSRAM)
SI (1) SI3436022T1 (OSRAM)
SM (1) SMT202200300T1 (OSRAM)
WO (1) WO2017173358A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205362B2 (ja) 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
SMT202100226T1 (it) 2015-07-06 2021-05-07 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055263T2 (hu) 2016-07-07 2021-11-29 Sage Therapeutics Inc 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
ES3038660T3 (en) 2016-10-18 2025-10-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
CN119350419A (zh) * 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2024520805A (ja) 2021-06-11 2024-05-24 セージ セラピューティクス， インコーポレイテッド アルツハイマー病の治療のための神経活性ステロイド
WO2023049295A1 (en) 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025021193A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (OSRAM) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
US4358406A (en) 1981-07-27 1982-11-09 Wisconsin Alumni Research Foundation 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0752860B1 (en) 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of gaba receptor
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
CA2205919A1 (en) 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
DE69634039T2 (de) 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
RU2182909C2 (ru) 1995-06-23 2002-05-27 Ново Нордиск А/С Стероиды, способ регулирования мейоза
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2331299A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
IL146230A0 (en) 1999-04-29 2002-07-25 Purdue Pharma Ltd 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6376530B1 (en) 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
EP1392713B1 (en) 2001-05-03 2007-10-17 The University of Chicago Liver x receptor agonists
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
AU2002360489A1 (en) 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
PL213697B1 (pl) 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
CN102727501A (zh) 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
GB0216621D0 (en) 2002-07-17 2002-08-28 Imaging Res Solutions Ltd Imaging compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
WO2004048364A1 (en) 2002-11-22 2004-06-10 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
KR101358078B1 (ko) 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
PL2711371T3 (pl) 2006-11-21 2018-06-29 Asarina Pharma Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20110118353A1 (en) 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
JP2011505357A (ja) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X-RECEPTOR AGONISTS
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
JP6205362B2 (ja) * 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
WO2013054822A1 (en) 2011-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CN104136452A (zh) * 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
RS57390B1 (sr) 2012-12-18 2018-09-28 Univ Washington Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja
JP2016505038A (ja) 2013-01-23 2016-02-18 スファエラ ファーマ プライベート リミテッド ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
AU2014243819A1 (en) * 2013-03-13 2015-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3049089B1 (en) 2013-09-25 2019-08-21 Van Andel Research Institute Highly potent glucocorticoids
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107405352A (zh) 2014-10-07 2017-11-28 萨奇治疗股份有限公司 神经活性化合物及其使用方法
SMT202100226T1 (it) 2015-07-06 2021-05-07 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
EP3319610A4 (en) 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055263T2 (hu) 2016-07-07 2021-11-29 Sage Therapeutics Inc 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
CN119350419A (zh) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
ES3038660T3 (en) 2016-10-18 2025-10-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
CN110945006A (zh) 2017-06-23 2020-03-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
SG10202110563YA (en) 2017-11-10 2021-11-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
KR20240134889A (ko) 2021-12-13 2024-09-10 세이지 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 신경활성 스테로이드

Also Published As

Publication number Publication date
NZ746825A (en) 2024-07-26
RU2754130C2 (ru) 2021-08-27
CY1125230T1 (el) 2025-03-28
US12448409B2 (en) 2025-10-21
US11884697B2 (en) 2024-01-30
PL3436022T3 (pl) 2022-08-08
RS63280B1 (sr) 2022-06-30
JP2025131749A (ja) 2025-09-09
CN109195604A (zh) 2019-01-11
HUE059491T2 (hu) 2022-11-28
JP2023126904A (ja) 2023-09-12
JP7112331B2 (ja) 2022-08-03
WO2017173358A1 (en) 2017-10-05
LT3436022T (lt) 2022-06-27
ES2921010T3 (es) 2022-08-16
BR112018070123A2 (pt) 2019-02-05
RU2018138183A3 (OSRAM) 2020-05-26
JP2021167334A (ja) 2021-10-21
JP2019510051A (ja) 2019-04-11
SMT202200300T1 (it) 2022-09-14
CN114272249A (zh) 2022-04-05
CN109195604B (zh) 2023-11-14
AU2022291419A1 (en) 2023-02-02
US20240270784A1 (en) 2024-08-15
CA3019146A1 (en) 2017-10-05
AU2024278111A1 (en) 2025-01-02
AU2017240157A1 (en) 2018-10-25
EP3436022A4 (en) 2019-11-27
AU2022291419B2 (en) 2024-09-05
JP7693755B2 (ja) 2025-06-17
MA44526A (fr) 2021-06-02
US20190330259A1 (en) 2019-10-31
RU2018138183A (ru) 2020-05-12
EP3436022A1 (en) 2019-02-06
EP3436022B1 (en) 2022-03-09
JP7308886B2 (ja) 2023-07-14
DK3436022T3 (da) 2022-06-20
HRP20220716T1 (hr) 2022-09-02
SI3436022T1 (sl) 2022-08-31
AU2017240157B2 (en) 2022-10-20
PT3436022T (pt) 2022-07-04
US20210261598A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CA3019146C (en) Oxysterols and methods of use thereof
AU2021218230B2 (en) Oxysterols and methods of use thereof
AU2016289967B2 (en) Oxysterols and methods of use thereof
HK40004292A (en) Oxysterols and methods of use thereof
HK40004292B (en) Oxysterols and methods of use thereof
BR112018070123B1 (pt) Compostos oxiesteróis, composição farmacêutica compreendendo os referidos compostos e uso destes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314

EEER Examination request

Effective date: 20220314